In his article in the BMJ, “Psychiatry in crisis? Dr. Richard Smith, former editor of the BMJ (British Medical Journal) summarizes the message delivered by several speakers at a meeting also convened in June 2016. This meeting took place in Leiden, the . . . Continue reading →
Johnson & Johnson
May 2016: The State of Psychiatry — Child Psychiatrists at APA Meeting
Child psychiatrists at the annual meeting of the American Psychiatric Association in Atlanta, in May 2016, called for “big solutions to improving child mental health care,” recommending an aggressive drug algorithm approach for children. (Psychiatric News, June 16, 2016) This is a . . . Continue reading →
Jury Finds Johnson & Johnson Violated Consumer Protection Law
Johnson & Johnson officilas made a business decision to decieve doctors by lying about the diabetes risk: “how much commercial liability would we incur if we sent a similar letter about Risperdal”? Continue reading →
Janssen Admits Hiding Risperdal Risks / TMAP & Illinois Mental Health Screening
Janssen Pharma Admits Hiding Risperdal Drug Risks / TMAP & Illinois Mental Health Screening Plan Sat, 24 Jul 2004 The Miami Herald reports (below) that in a letter to doctors, Janssen Pharmacia, manufacturer of the highly promoted drug, Risperdal (risperidone), admitted “misleading . . . Continue reading →
Lilly to Add Suicide Warning to Strattera – Medicaid May shrink $5.5 Billion spending on Schizophrenia Drug
Lilly to Add Suicide Warning to Strattera – Medicaid May shrink $5.5 Billion spending on Schizophrenia Drug Thu, 29 Sep 2005 Reuters reports that Eli Lilly is adding a Black Box suicide warning to the Strattera label. Strattera has been promoted as . . . Continue reading →
Two-thirds foster care children in Mass on psych drugs_Globe /Psychiatry: Soviet Experience–American Fallacy
Two-thirds foster care children in Mass on psych drugs_Globe Psychiatry: Soviet Experience–American Fallacy Wed, 11 Aug 2004 The Boston Globe reports that 2/3 of children in state care in Massachusetts are being “treated” for mental illness with psychotropic drugs. Marie Parente, a . . . Continue reading →
AMA Serves Pharma Marketing Priority/ FDA To Add Warnings on ADHD drugs–Concerta, Ritalin, Strattera, Adderall
AMA Serves Pharma Marketing Priority/ FDA To Add Warnings on ADHD drugs–Concerta, Ritalin, Strattera, Adderall Wed, 29 Jun 2005 The FDA is finally taking note of the fact that many drugs prescribed for the treatment of psychiatric problems are CAUSING serious psychiatric . . . Continue reading →
Spitzer Expands drug Probe: Johnson & Johnson / New FDA analysis Confirms SSRI Risks to Kids – WSJ
Spitzer Expands drug Probe: Johnson & Johnson / New FDA analysis Confirms SSRI Risks to Kids – WSJ Thu, 5 Aug 2004 A front page article in The Wall Street Journal reports that a second FDA analysis of 25 clinical trials of . . . Continue reading →
Research Protection for Children
AHRP Campaign to Protect Children from Harm Oct 15: FDA Orders Black Box Warnings on Antidepressants labels and Patient Information Guides to Warn about Suicide risk Oct 3: BBC PANORAMA TONIGHT – Taken on Trust – 13 years-Medical Deception Sep 30: GSK . . . Continue reading →
Merck / Johnson & Johnson/ Lilly-Zyprexa: $690 Million settlement / a Flowering of Diabetes Drugs
Merck / Johnson & Johnson/ Lilly-Zyprexa: $690 Million settlement / a Flowering of Diabetes Drugs Fri, 10 Jun 2005 A cluster of news reports about three pillars of the pharmaceutical industry– Merck, Eli Lilly, and Johnson & Johnson–leave no doubt that this . . . Continue reading →
Drug safety Hearings-Sept-Congress/ FDA – Lilly Plans to Disclose Data
Drug safety Hearings-Sept-Congress/ FDA – Lilly Plans to Disclose Data Tue, 3 Aug 2004 A hearing about the possible connection between suicide and antidepressant drugs will be held on Aug 4, by the California Senate by Sen. Tom Torkalson, chairman of the . . . Continue reading →
Dr. Wolpe’s Accusations and Dr. Healy’s Response
Dr. Wolpe’s Accusations and Dr. Healy’s Response —–Original Message—– From: Paul Root Wolpe Sent: Tuesday, October 28, 2003 4:30 PM To: VERACARE Subject: Re: Ethics of U Penn surgical “drug implant” experiment Vera, We will have to agree to disagree, so this . . . Continue reading →